-+ 0.00%
-+ 0.00%
-+ 0.00%

Jasper Therapeutics completes acquisition of Kira Pharmaceuticals in all-stock deal

PUBT·07/16/2026 21:15:21
Listen to the news
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals in all-stock deal
  • Jasper Therapeutics completed an all-stock acquisition of complement-therapy developer Kira Pharmaceuticals, forming a combined immunology-focused drug developer.
  • Deal paired with a private placement of non-voting convertible preferred stock expected to raise about USD 132 million gross.
  • Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for a USD 12 million upfront payment, with additional milestones possible.
  • Pro forma cash at closing, including the financing and out-licensing proceeds, is expected to fund operations into the second half of 2028.
  • Shares will continue trading on Nasdaq under the ticker JSPR, with focus on KP-104, briquilimab, and KP-701 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607161715PRIMZONEFULLFEED9763720) on July 16, 2026, and is solely responsible for the information contained therein.